By inhibiting interleukin-1 beta (IL-1β) -induced inflammation and CRP production and resulting in improvements in CVD events through inhibiting IL-1β, canakinumab, in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) study [163] and gemcabene have shown hypolipidemic and anti-inflammatory properties, in addition to LDL lowering activity, which offers an added benefit to CVD patients [164]. This evidence concerns the gene IL1B and Venous thrombosis.